

Special Issue

Role of Microbiota in Colonic Inflammation and Colon Cancer

Message from the Guest Editor

The microbiota, a biological ecosystem that communicates strongly with the host, has been widely identified as an emerging factor of inflammation, which further impacts cancer. Colon cancer, one of the most common malignancies worldwide, is frequently associated with dramatic alterations in the microbial composition of the tumor. Although the effects of several specific bacterial strains on colon inflammation and cancer have been reported, how the microbiota communicates with the colon to promote inflammatory responses is still poorly understood. In this Special Issue, we focus on the role of the microbiota in colon inflammation and cancer, especially its detailed molecular mechanism and clinical treatment, aiming to develop management strategies for colon-related diseases through targeting the microbiota.

Guest Editor

Dr. Jianan Zhang

Cutaneous Biology Research Center, Mass General Hospital, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

31 July 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/209134

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).